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Background: Laparoscopic adrenalectomy has become the gold standard in most patients with adrenal
tumors. It is unclear; however, at what size an adrenal neoplasm should be resected by means of an open
or a laparoscopic approach. The aim of the present study was to compare the outcomes of laparoscopic
adrenalectomy for large tumors with smaller tumors.
Methods: A prospective study of patients who underwent adrenalectomy during the period 2006–2009
was undertaken. The patients were divided into 2 groups according to the tumor size. Group 1 (n¼ 29)
consisted of patients presenting tumors smaller than 5 cm in diameter; group 2 (n¼ 31) consisted of
patients with tumors larger than 5 cm in diameter.
Results: Two of the 29 tumors in group 1 (6.8%) were malignant at ﬁnal histology. However, 11 of the 31
tumors in group 2 (35.4%) were malignant. There were no signiﬁcant differences between operating time
and complications of groups 1 and 2. The intra-operative blood loss was signiﬁcantly lower in group 1
than in group 2.
Conclusion: Laparoscopic adrenalectomy is a reasonable procedure for selected large adrenal tumors
when a complete resection is technically feasible and there is no evidence of local invasion.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Background
Since the initial description of laparoscopic adrenalectomy (LA)
in 1992 by Gagner et al.,1 LA is today considered the ﬁrst-choice
treatment of most adrenal diseases and the indications of this
technique have been greatly expanded.2–5 Retrospective compar-
ison studies have consistently shown the laparoscopic approach to
have lower complication rates, less operative blood loss, less
postoperative pain, less narcotic requirements, shorter hospital
stays, earlier return to activity and diet, and lower overall costs than
open adrenalectomy.6–10
Tumor size is usually considered an indicator of malignancy.
Tumors larger than 5 cm in diameter are likely to be malignant but
remain relatively insensitive and nonspeciﬁc.11–13 It is uncertain if
the laparoscopic resection of large potentially malignant adrenal
tumors is appropriate due to concern over incomplete resection
and local recurrence. For this reason, selection of those suitable for
laparoscopy is practiced by many surgeons and this may bias
outcomes. Some authors still suggest that patients with benign
adrenal lesions larger than 5–6 cm should not be treated with LA: þ90 212 6319771.
ciates Ltd. Published by Elsevier Ltbecause of the longer operative time, the elevated risk of bleeding
due to the numerous vessels surrounding the neoplasia, and the
risk of capsular disruption.14–16 Several centers, on the other hand,
demonstrate that large potentially malignant adrenal tumors with
no radiological evidence of invasion may be treated safely and
effectively through a laparoscopic approach.11–13,17–192. Aim of the study
The aim of the present study was to assess the safety of LA for
large adrenal tumors and to compare the results of LA for tumors
5 cm with those <5 cm from a consecutive series of patients.3. Patients and methods
3.1. Patients
In our Department of Surgery at the Istanbul Faculty of Medicine
between June 2006 and January 2009 a total of 68 consecutive LA
were performed in 60 patients: 52 unilateral and 8 bilateral. There
were 44 women and 16 men with a mean age of 44.1 years (range
23–76 years). The patients were divided into 2 groups according to
the tumor size. Group 1 (n¼ 29) consisted of patients presentingd. All rights reserved.
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patients with tumors larger than 5 cm in diameter. The study plan
was reviewed and approved by our institutional ethical committee,
and informed consent was obtained for all patients.
3.2. Pre-operative evaluation
Bodymass index (BMI) was calculated as the ratio of weight (kg)
divided by height (m2). All patients underwent the following
endocrine workup aimed to screen for pheochromocytoma,
hyperaldosteronism, hypercortisolism, and virilizing or feminizing
tumors. Computed tomography (CT) was used routinely to predict
the benign or malignant status and size of the lesion. Tumor size
was measured with the largest diameter of the mass on CT or
magnetic resonance imaging (MRI). When local invasion was sus-
pected on CT, MRI angiography was used to test for major vascular
involvement. A diagnosis of possible adrenal carcinoma was based
on the patient history and radiology ﬁndings. Radiological charac-
teristics of malignancy included: tumor size larger than 6 cm, local
invasion, irregular margins or tumor heterogeneity.
Patients with Cushing’s lesions were prescribed appropriate
steroid replacement to compensate for hypofunction of the adrenal
gland(s). Patients with pheochromocytomas received appropriate
pre-operative blockade with phenoxybenzamine and a b-blocker.
3.3. Inclusion and exclusion criteria
Indications for adrenalectomy included: hormone secreting
tumors and all tumors>6 cm. Resection of non-functioning adrenal
tumors (<6 cm) was indicated for patients with evidence of tumor
growth on serial imaging. The presence of mixed hormonal secre-
tion, virilization, or elevated dehydroepiandrosterone sulfate
(DHEA-S) in the absence of radiologic evidence of malignancy was
not a pre-operative contraindication to the LA. Patients who man-
ifested pre-operative radiologic features of malignancy, such as
tumor invasion of the surrounding structures, lymphadenopathy, or
systemicmetastaseswereperformed open adrenalectomyandwere
excluded this study. Two open adrenalectomies were performed in
the same period because of the evidence of extension into adjacent
tissues necessitating a wide excision of adjacent inﬁltrated struc-
tures (adrenalectomyþ nephrectomyþ splenectomy).
3.4. Surgery
All adrenalectomies were performed by two surgeons. The LAs
were performed by a transperitoneal ﬂank approach in the lateral
decubitus position. Access was achieved through 3 port sites in left-
sided lesions and 4 in right-sided lesions, the fourth port needed for
liver retraction. For right adrenalectomy, the right lobe of the liver
is fully mobilized by division of the triangular ligament. With the
liver retracted cephalad and medially rotated, the peritoneum
overlying the right adrenal gland is dissected using electrocautery,
showing the right adrenal vein. After the right adrenal vein is
located, it is doubly clipped and cut. Occasionally, a vascular
stapling device is used to control the adrenal vein. The remaining
dissection is performedwith vessel sealing system. All tumors were
extracted in their entirety, along with the adrenal gland and the
surrounding fatty (Fig. 1). They were collected in a plastic bag to
allow detailed histomorphological classiﬁcation. For left-sided
resection, the splenophrenic, splenocolic, and splenorenal liga-
ments are divided using electrocautery. The spleen and pancreatic
tail are then rotated medially. The peritoneal dissection is per-
formed until the left renal vein is reached, exposing the adrenal
gland and vasculature. The resection then proceeds as previously
described for the right adrenal gland. Drainage was used routinely.Fragmentation of the gland was recorded. Operative time was
deﬁned as the time from skin preparation to closure of the skin
incisions. Operative blood loss was measured from that collected in
the suction device. All patients received prophylaxis for deep vein
thrombosis. Nasogastric suction was not used postoperatively. Oral
ﬂuids were given on the next day.
Age, gender, BMI, indications for adrenalectomy, clinicopatho-
logical tumor characteristics, operating time, intra-operative blood
loss, intra-operative complications, andconversion fromlaparoscopic
to open adrenalectomy, postoperative complications, and hospital
stay were recorded and compared these parameters in both groups.
3.5. Statistics
Data were analyzed using SPSS 11.0 for Windows. Results were
expressed as means SD. Data comparisons were performed by
Mann Whitney-U and chi-squared tests. Correlation analyses were
performed using non-parametric Spearman’s correlation and two-
way analysis of variance tests. Study parameters that had non-
Gaussian distributions were transformed to square root values.
Results were considered statistically signiﬁcant, when the two-
tailed p-value was less than 0.05.
4. Results
4.1. Patient characteristics
Indications for laparoscopic adrenalectomy were nonfunctional
tumor (n¼ 28), Cushing’s syndrome (n¼ 12), pheochromocytoma
(n¼ 8), aldosteronoma (n¼ 6), and Cushing’s disease (n¼ 6). The
mean tumor size was 5.4 2.8 cm (range 2–17 cm). Twenty-ﬁve
tumors were on the right side and twenty-seven on the left. The
mean operating time was 91.7 33 min (range 45–210 min) for
unilateral LA and 199.4 61 min (range 155–255 min) for bilateral
LA. Intra-operative blood loss and postoperative hospital stay
were 79109 ml (range 20–750) and 3.3 2.3 days (range 2–15).
The mean operating time of left-sided adrenalectomies
(114.5 37 min) was signiﬁcantly higher than that of right-sided
adrenalectomies (73.3 31 min), (p¼ 0.001). The LAs were
performed by the two surgeons experienced in endocrine and
laparoscopic surgery. Therewas not a signiﬁcant difference in intra-
operative blood loss (70.4 47 ml vs. 77144 ml) and operating
times (87.6 32 min vs. 93.2 25 min) between the two surgeons.
Twenty of our patients had previous abdominal surgery. No patient
required a conversion to conventional open or hand-assisted
surgery. There was no postoperative mortality. Complications
occurred in 5 (8.3%) patients: pancreatic ﬁstula (1), wound infec-
tion (1), respiratory infection (1), hemodynamic change (1) and
capsular disruption (1).
4.2. The evaluation of the patients according to the tumor size
The mean ages were 45.412 years in group 1 and 42.8 12
years in group 2. The female/male ratios were 23/6 and 21/10 in
groups 1 and 2, respectively. Mean tumor size was 3.5 cm in group
1 (2–5 cm) and 7.2 cm in group 2 (5–17 cm). There were no
signiﬁcant differences between age, gender, tumor localization,
operating time, prior abdominal surgery, and complications of
groups 1 and 2. The intra-operative blood loss was signiﬁcantly
lower in group 1 (52.764 ml) than in group 2 (93.3130 ml)
(p¼ 0.001) (Table 1).
Complications developed in 2 patients in the group with tumor
sizemore than 5 cm. Capsular disruption in one patient with a 12 cm
nonfunctional adenoma occurred at the end of the dissection and on
ﬁnal pathology, that patient found to have an adrenocortical
Fig. 1. Resected adrenal tumor with surrounding fatty (A) liposarcoma; (B) adrenocortical carcinoma; (C) malignant pheochromocytoma.
Y. Erbil et al. / International Journal of Surgery 7 (2009) 266–271268carcinoma. Hemodynamic change (labile intra-operative blood
pressure) occurred in one patient with pheochromocytoma despite
adequate pre-operative blockade with phenoxybenzamine and
propranolol and blood transfusion was required for intra-operative
bleeding. Three of 5 complications which were occurred were in the
patient with tumor size less than 5 cm. Thesewere pancreatic ﬁstula,
wound and respiratory infection. The patient developed pancreatic
ﬁstula that resolved spontaneously after 2 weeks.
Two of the 29 tumors in group 1 (6.8%) were malignant at ﬁnal
histology. However, 11 of the 31 tumors in group 2 (35.4%) were
malignant. Malignant tumors were bilateral malignant pheochro-
mocytoma in one case, adrenocortical carcinoma in three cases,
liposarcoma in one case and adrenal metastases in eight patients.
Twelve patients were classiﬁed as having nonfunctional adrenal
tumors. No patient underwent pre-operative ﬁne needle aspiration
biopsy.Table 1
Comparison of the groups.
Variable Group 1 (5 cm<) Group 2 (5 cm) p
No. patients 29 31 –
Tumor size (cm) 3.5 7.2 2.9 0.001
Mean age (years) 45.4 12 42.8 12 NS
Male/female 23/6 21/10 NS
BMI (m2/kg) 32.7 6.2 27.5 5.1 0.001
Left/Right 14/8 13/17 NS
Prior abdominal surgery (n) 7 5 NS
Operating time (min) 95.7 38 85.6 36 NS
Blood loss (ml) 52.7 64 93.3 130 0.001
No. complication (n) 3 2 NS
Hospital stay (day) 3.6 2 3 2 NSEight of the 13 patients had past histories of extra-adrenal
malignancies (from lung carcinoma in seven cases and esophageal
squamous cell carcinoma in the one patient). The difﬁculty of
dissection, dense adhesions, and unusual and numerous retroper-
itoneal feeding vessels were not observed intraoperatively. At
operation there was no evidence of local invasion or adenopathy.
All of the adrenal glands were removed intact and had negative
margins on pathologic examination. However, the one patient with
ACC in whom there was capsular disruption of the tumor during
dissection underwent.4.3. Correlations
Strongly positive correlations were found between tumor size
and intra-operative blood loss (r¼ 0.521, p¼ 0.0001). There were
no correlations between tumor size and operating time. Signiﬁcant
positive correlations were also found between operating time and
BMI (r¼ 0.610, p¼ 0.0001), Fig. 2.4.4. Follow-up
The median follow-up for the entire group of patients was 18
months (range, 4–30 months). Table 2 depicts follow-up informa-
tion on thirteen patients with pathologically proven malignancies.
One patient with metastatic carcinoma presented with local recur-
rence and liver metastases 14 months after surgery and died. One
patient with ACC had multiple metastases 6 months after surgery
and died 12 months after. In both cases there was no evidence of
tumor capsular rupture or spillage of tumor cells (Table 2).
Fig. 2. Relationship between intra-operative blood loss and tumor size (A); BMI and
operating time (B).
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LA has become the preferred method for the removal of benign
functioning and non-functioning tumors of the adrenal gland.
Despite the success of LA in patients with small adrenal tumors,
there has been a reluctance to use this approach in patients with
large adrenal tumors.2–4
Size is an important variable in predicting malignancy of an inci-
dentally discovered adrenal mass. Tumors larger than 6 cm in diam-
eter are likely to bemalignant, however many adrenal adenomas are
larger than 6 cm.17–19 According to the NIH consensus statement forthe management of the incidentally adrenal mass, the incidence of
adrenocortical carcinomas increases from 2% in tumors <40 mm, to
6% in tumors 41–60 mm in size, to 25% in tumors>60mm.20 If size is
the sole criterion on which the operative approach is based, many
patients with benign large adrenal tumors will have an unnecessary
open adrenalectomy that might increase their morbidity.11–13 In our
series, 11 of 31 adrenal tumors greater than 5 cm were malignant,
whereas almost 64.6% of these large tumors were benign.
Larger tumor size, primary and metastatic disease, bilateral
lesions or previous surgery in the adrenal region have been sug-
gested limitation for laparoscopy by some investigators,2,4,21 but
these limitations depend on the surgeon’s experience and skill.
Although it is well known that the size cannot be considered as an
absolute contraindication for LA, the maximum tumor size above
which a laparoscopic approach is contraindicated has not been
determined.17–19 Several studies in the literature report removal of
masses as large as 15 cm; however, because of the increased inci-
dence of malignancy at this size and technical limitations of
extraction, this surgery is rarely done.18,19
A diagnosis of possible adrenal carcinoma was based on the
patient history and radiology ﬁndings. Imaging studies can help the
surgeons to evaluate a malignant lesion; abdominal ultrasounds, CT
and MRI can demonstrate irregular tumor margins, local invasion of
the periadrenal tissue, heterogeneity, and hyperdensity.22,23 CT was
used routinely to predict the benign or malignant status and size of
the lesion. Tumor sizewasmeasuredwith the largest diameter of the
mass on CTorMRI. When local invasionwas suspected on CT, MRI or
CTangiographywasused to test formajorvascular involvement.None
of thepatientshadpre-operative imagingstudies that irregular tumor
margins, tumor invasion of the surrounding structures, lymphade-
nopathy, or systemic metastases. However, 8 of the 13 patients had
past histories of extra-adrenal malignancies. Our patients with ACC
had pre-operative imaging studies that suggested malignant poten-
tial and pre-operative diagnosis was nonadenomatous lesions. We
have used the pre-operative imaging rather than tumor size and
selected our patients for laparoscopic adrenalectomy.
Todayabsolute contraindications for LA include tumorswith gross
local invasion and invasive adrenocortical carcinomas.2,21 Computed
tomography (CT) scan and CT angiography, as well as magnetic
resonance (MR) imaging are recommended in the pre-operative
workupofadrenal lesion toassess thepresenceof signsofmalignancy
or local invasion. These modalities can demonstrate irregular tumor
margins, local invasion of the periadrenal tissue, heterogeneity, and
hyperdensity, but these predictors of malignancymay also be seen in
benign tumors. CT can predict a malign lesion when it has a high
attenuation values (>10 HU units). MRI T2-weighted signal intensity
is low in adenoma. CT and MRI characteristics of adrenal tumors are
also used to help to determine their risk of malignancy but are not
always conclusive.22,23 The intra-operative features indicative of the
malignant nature of an adrenal tumor include local ﬁxity; invasion of
the pancreas, spleen, or superior pole of the kidney; venous throm-
bosis; and lymphadenopathy.17–19 If evidence of local invasion is
present, it is recommended that the procedure be converted to
a hand-assisted procedure, or the open technique can be used.2,17,18
Our data show that patients with large tumors with no preoperative
or intra-operative evidence of malignancy can undergo successful
laparoscopic adrenalectomy.
With improved imaging techniques, only a small proportion of
adrenal masses require percutaneous biopsy for diagnosis.22,23 In
a recent study by Harisinghani et al.,24 the negative predictive value
(NPV) of adrenal biopsies was shown to be between 98 and 100%.
Percutaneous CT-guided adrenal biopsy is a relatively safe proce-
dure in patients with a known extra-adrenal malignancy.
Tumor size is usually considered an indicator of malignancy.11–15
It is unclear, however, at what size an adrenal neoplasm should be
Table 2
Follow-up of the patients with adrenal malignancies.
Patient no. and carcinoma Initial diagnosis Tumor size (cm) Local recurrence Distant metastasis Survival (months)
1. Primary ACC Nonfunctional tumor 10 – – alive (28)
2. Primary ACC Nonfunctional tumor 6 þ (6 mo) liver, lung death (12)
3. Primary ACC Nonfunctional tumor 13 – – alive (4)
4. Liposarcoma Myelolipoma 17 – – alive (11)
5. Malign pheochromocytoma Pheochromocytoma 8 – – alive (24)
6. Metastatic lung carcinoma Nonfunctional tumor 5 þ (7 mo) liver death (14)
7. Metastatic lung carcinoma Nonfunctional tumor 3 – – alive (24)
8. Metastatic lung carcinoma Nonfunctional tumor 4 – – alive (18)
9. Metastatic lung carcinoma Nonfunctional tumor 8 – – alive (20)
10. Metastatic lung carcinoma Nonfunctional tumor 5 – – alive (12)
11. Metastatic lung carcinoma Nonfunctional tumor 5 – – alive (30)
12. Metastatic lung carcinoma Nonfunctional tumor 6 – – alive (22)
13. Metastatic SCC Nonfunctional tumor 5 – – alive (5)
ACC: adrenocortical carcinoma; SSC: squamous cell carcinoma.
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The fears that laparoscopic resection of large adrenal tumors may
result in inadequate removal or capsular disruption of a malignant
tumor and an increase in the risk of a local or port-site recurrence of
the disease. Recurrences may due to the incomplete resection or
capsular disruption of the tumor during dissection. These intra-
operative complications are also observed during open surgery.
What is most important is the ability of the surgeon to perform
a safe and complete resection of the adrenal tumor, regardless of
the size of the tumor.11–15
LA for primary and metastatic adrenal tumors is controversial.
Some authors consider malignancy to be an absolute contraindica-
tion to laparoscopy.2,11–14 However, for selected cases, some studies
havedemonstrated results similar to those foropensurgery. Primary
ACC is a raremalignancyandhas a5-year survival, ranging from16 to
60%.25–27 Even when patients have localized disease and complete
tumor resection, systemic metastasis and local recurrences occur in
at least two thirds of cases. Onemust keep inmind that recurrences
are alsoobservedafter openadrenal surgery for stage I and II tumors.
Themain risk during laparoscopic or open adrenalectomy for ACC is
capsular disruption. Once the capsula has been violated, there is
a high risk of intra-abdominal neoplastic dissemination. LA is not yet
considered standard treatment for ACC and metastases of the
adrenal gland because of concerns regarding long-term outcome
and the risk of tumor cell spillage.2,25–28 We believe that longer
follow-up is mandatory before deﬁnitive recommendation can be
drawn about laparoscopic adrenalectomy in primary or metastatic
adrenal malignant masses.
The laparoscopic resection of a large adrenal tumor can be
technically challenging. Larger tumors have a larger surface to
dissect and can require a longer operative time. The exposure also is
trying because the space available in this area is limited. In our
study, tumor size was not signiﬁcant variable of operating time,
whereas BMI was only independent signiﬁcant variable of oper-
ating time. The patients who are overweight as in the patients with
Cushing disease have an increased incidence of adipose tissue;
excessive operating time is necessary to remove adrenal glands.
Frequently, large masses have unusual and numerous retroperito-
neal feeding vessels that require tedious dissection and result in
more intra-operative blood loss. We also found that larger adrenal
tumors are signiﬁcantly associated with intra-operative blood loss.6. Conclusion
There is still no consensus regarding themaximumtumor size for
LA. If there is no evidence of the local invasion, large and potentially
malignant adrenal tumors can be safely removed laparoscopically
provided that the oncological surgical principles are observed.Conﬂict of interest
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